The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma

Nanni Hua1,2 · Anxian Chen3 · Chen Yang4 · Hui Dong5 · Xianglei He6 · Guoqing Ru6 · Xiangmin Tong2 · Feifei Zhou7 · Shibing Wang2

Received: 21 November 2021 / Accepted: 19 May 2022 / Published online: 1 July 2022 © The Author(s) 2022

Abstract
Background Fibrinogen-like-protein 1 (FGL1), a member of the fibrinogen-related protein (FREP) family, is a major ligand of the immune inhibitory receptor lymphocyte-activation gene 3 (LAG-3). While FGL1 is strongly implicated in the development and prognosis of a variety of diseases, its role in hepatocellular carcinoma (HCC) is still disputed. Therefore, the role of FGL1 expression in the progression and prognosis of HCC was investigated.

Methods and results In the present study, bioinformatics analysis was first used to probe the expression profile of FGL1 in multiple malignant tumor tissues and paired normal tissues, and to explore the possible relationship between FGL1 and prognosis of HCC patients. Thereafter, the expression levels of FGL1 were determined and compared in human HCC cell lines, HCC tissues, peri-tumor tissues and normal liver tissues by western blot analysis. Furthermore, tissue microarrays were used to detect the expression of FGL1 through immunohistochemical staining and to verify whether the FGL1 expression level was associated with clinicopathological features and the prognosis of HCC patients. The results showed that FGL1 was downregulated significantly in most of the HCC cells lines and HCC tissues, corresponding to the results of the bioinformatics and western blot analyses. FGL1 expression level in HCC was found to be correlated to Edmondson grade and metastasis of the HCC. Additionally, high FGL1 expression was associated with better overall survival in HCC patients, suggesting that FGL1 could function as a tumor suppressor.

Conclusions The expression level of FGL1 can be correlated with the progression and prognosis of HCC, suggesting its potential as a prognostic biomarker.

Keywords Fibrinogen-like-protein 1 · Hepatocellular carcinoma · Progression · Prognosis · Tumor suppressor

Abbreviations

FREP Fibrinogen-related protein
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GEPIA Gene expression profiling interactive analysis

Nanni Hua and Anxian Chen have contributed equally to this work.

* Feifei Zhou
5510025@zju.edu.cn
* Shibing Wang
wangshibing@hmc.edu.cn

1 The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310000, China
2 Cancer Center, Molecular Diagnosis Laboratory, Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang, People’s Republic of China
3 School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, Guangdong, China
4 Department of Ultrasound, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang, China
5 Department of Stomatology, Bengbu Medical College, 2600 Donghai Avenue, Bengbu 233030, China
6 Departments of Pathology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang, China
7 Departments of TCM Gynecology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
Introduction

According to 2020 data, hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed and the third most deadly malignant tumor in the world, with 905,677 new cases and 830,180 reported deaths [1]. Due to the insidious onset of HCC and the limited availability of targeted drugs, the five-year survival rate of HCC patients in China is only 14.1% [2]. Reliable prognostic indicators could improve the situation, but the sensitivity and specificity of current biomarkers are inadequate [3, 4]. Therefore, it is critical to seek effective biomarkers which can predict the prognosis and guide the treatment for HCC to further improve clinical outcomes.

Fibrinogen-like-protein 1 (FGL1), also known as hepasocin or hepatocyte-derived fibrinogen-related protein 1 (HFREP1), is a liver-secreted protein with two disulfide-linked 34kD homodimers [5, 6]. FGL1 was first found to be over-expressed in HCC [7, 8]. As a member of fibrinogen-related protein (FREP) family, FGL1 is closely correlated with the development and prognosis of a variety of diseases. Moreover, a previous study suggested that FGL1 can activate mitosis, increase metabolic activity, and is closely related to obesity [9]. Under normal physiological conditions, FGL1 is involved in fine-tuning systemic inflammation by facilitating an interaction between the liver and other peripheral tissues [10]. FGL1 can also stimulate the EGFR/ERK cascade to promote hepatocyte proliferation via the Src-dependent pathway [11, 12]. In addition, FGL1 acts as a liver regeneration factor with previously reported increase in expression during the liver regeneration [13–15]. In summary, FGL1 has a vital effect on liver regeneration and protection. However, FGL1 expression not only affects hepatocyte regeneration but also regulates the growth and proliferation of tumor cells [16, 17]. Targeted disruption of FGL1 has been shown to accelerate the development of HCC, which suggests that FGL1 could be a potential therapeutic target in HCC patients [17]. Another study recently found that FGL1 is an important component of the FGL1-LAG-3 pathway that promotes the growth of malignant tumors, suggesting that the double blockade of FGL1 and PD-1/PD-L1 could become a therapeutic alternative for patients for whom anti-PD therapy is ineffective [18]. Interestingly, while FGL1 is downregulated in HCC compared to normal tissues, it has been found to be upregulated in melanoma, lung, breast, and colorectal cancers [6]. Overall, the role of FGL1 in HCC remains controversial and warrants further investigation.

The present study employs bioinformatics analysis to probe the expression profile of FGL1 in multiple malignant tumor tissues and paired normal tissues, and to explore the possible relationship between FGL1 and HCC prognosis. Moreover, western blot was used to further compare the expression levels of FGL1 in HCC cell lines, HCC tissues, peri-tumor tissues and normal liver tissues. Furthermore, a large sample size was used to determine whether FGL1 expression level is associated with the clinicopathological features and prognosis of HCC. The results of the present study shed light on a possible prognostic biomarker which could help in the development of new treatments against HCC as well as in the evaluation of HCC prognosis.

Materials and methods

Patient population and tissue samples

Samples from 237 HCC patients, admitted in the Zhejiang Provincial People’s Hospital between January 1998 to December 2011, were included in the study. Samples from tumor, peri-tumor, and normal liver tissues were collected from the participants, in addition to their clinical information (including data about age, gender, tumor size, tumor number, Edmondson grade, metastasis, microvascular invasion, hepatitis B surface antigen [HBsAg], cirrhosis, alpha fetoprotein [AFP] and so on). All participants were followed up for more than 5 years from the time of their surgical operation until December 2018 or patient death. All participants were in the 25–90 years age group, with an average age of 57.5 years. Of the 237 participants, 47 (19.8%) were women and 190 (80.2%) men. At initial diagnosis, 59.2% of the participants had HCC tumors less than or equal to 5 cm in diameter, while 40.8% patients had tumors greater than 5 cm in diameter. Nearly 65.2% of the HCC patients suffered from Edmondson grade I/II disease, while 34.8% suffered from grade III HCC. The numbers of patients with and without metastasis were 19 (8.3%) and 210 (91.7%), respectively. The study was authorized by the Ethics Committee.

| HBSAg | Hepatitis B surfaceantigen |
|-------|---------------------------|
| HCC   | Hepatocellular carcinoma  |
| HFREP1| Hepatocyte-derived fibrinogen-related protein 1 |
| IHC   | Immunohistochemistry      |
| LAG-3 | Lymphocyte activation gene 3 |
| LIHC  | Liver hepatocellular carcinoma |
| LKB1  | Liver kinase B1           |
| NSCLC | Non-small cell lung cancer |
| OS    | Overall survival          |
| PVDF  | Polyvinylidene difluoride |
| SDS-PAGE | Sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| TBST  | Tris buffered saline with tween |
| TCGA  | The Cancer Genome Atlas   |
| TMA   | Tissue microarray         |
| TPM   | Transcripts per million   |
of the Zhejiang Provincial People’s Hospital (2019KY232). Importantly, informed consent was obtained from all study participants.

**Cell culture**

Human HCC cell lines (HCC-LM3, SK-Hep1, SMMC-7721, SNU182, C3A, HepaG2, Huh7, Hep3B) and human normal liver cell L02 were purchased from the ATCC. All cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM, Gibco, USA) with 10% fetal bovine serum (Gibco, USA), 100 units/mL penicillin, and 100 µg/mL streptomycin (Life Technologies, USA) under 5% CO₂ at 37 °C.

**Western blot assay**

Total proteins were extracted from the HCC tissue samples and cell lines in RIPA buffer supplemented with a protease inhibitor cocktail (Roche, Switzerland). A BCA kit (Beyotime, China) was used to measure the protein concentration. The protein samples were boiled at 100 °C for 5 min, and separated using 12% SDS-PAGE. The separated proteins were electro transferred onto 0.22 μm PVDF membranes (Roche, Switzerland), and sealed with 5% skim milk for 1 h. Next, the membranes were incubated with anti-GAPDH (Bioworld, USA, 1:2000 diluted) or anti-FGL1 (ab197357, Abcam, England, 1:1000 diluted) primary antibody at 4 °C overnight, followed by washing in tris-buffered saline with 0.1% (v/v) Tween® 20 (TBST) for 3 × 10 min. Subsequently, the membranes were incubated with the secondary antibody (1:2000 diluted) for 1 h, followed by washing in TBST for 3 × 10 min. Thereafter, the FDbio-Dura enhanced chemiluminescence (ECL) reagent (FD8020, FDbio science, China) was used to detect signals under the Alpha Innotech Fluor Chem-FC2 imaging system (Protein Simple, USA). GAPDH was used as an internal control.

**Bioinformatics analysis of FGL1 expression in HCC**

The Gene Expression Profiling Interactive Analysis 2 (GEPIA 2) (http://geopia2.cancer-pku.cn/#index) online website was used to analyze the FGL1 levels in malignant tumors. Firstly, the dot plot gene expression profile of FGL1 was obtained by performing a single gene analysis across multiple malignant tumor tissues and paired normal tissues. Secondly, expression DIY was used to analyze FGL1 expression in HCC with a box plot, setting the parameters as follows: gene; Gene A, FGL1; [Log2FC] Cutoff, 1; p-value Cutoff, 0.01; Multiple Datasets; Datasets Selection (Cancer name), LIHC; Log Scale, Yes; Jitter Size, 0.4; Match Normal data, Match TCGA normal and GTEx data. Thereafter, a possible relationship between FGL1 and the clinical stage of HCC was explored by using the UALCAN online website (http://ualcan.path.uab.edu/). Finally, a Kaplan–Meier curve of overall survival (OS) was plotted using GraphPad Prism 8.0 on the basis of the OncoLnc Database (http://www.oncolnc.org/).

**Immunohistochemistry staining**

Tissue specimens, including HCC tissues and adjacent normal liver tissues, were fixed with formalin and embedded in paraffin. The 5-µm-thin paraffin-embedded tissue microarray (TMA) sections subsequently obtained were dewaxed in xylene (Sinopharm, China) and serially rehydrated in alcohol solutions (Sinopharm, China). Thereafter, the tissue sections were incubated with 3% hydrogen peroxide (Sinopharm, China) in order to block endogenous peroxidases. To reduce nonspecific protein binding, the sections were subsequently incubated in 1% (w/v) bovine serum albumin (BSA; Sigma, Germany) for 20 min. The sections were then incubated with an anti-FGL1 polyclonal antibody (1:50; HuaBio, Hangzhou, China) at 25 °C for 1 h, followed by incubation with a biotinylated secondary antibody (MXB, Fuzhou, China) at 37 °C for 30 min. Thereafter, the TMA sections were stained with 3,3′-diaminobenzidine (DAB) chromogen (Gene Tech, Shanghai, China), followed by counterstaining with Mayer’s hematoxylin (HuaBio, Hangzhou, China). Finally, all tissue sections were destained with alcohol and xylene. The sections were observed using an inverted fluorescence microscope. The immunohistochemical staining of FGL1 was scored into four grades, judged independently by two pathologists, based on the intensity and proportion of the positively stained cells. In the present study, grade 1 was assigned for low FGL1 expression, followed by higher grades for higher FGL1 expression.

**Statistical methods**

SPSS 25.0 (Chicago, IL, USA) was used to analyze all data. An independence test of categorical variables was performed using chi-square analysis or Fisher’s exact test. In addition, the Kaplan–Meier analysis was performed to evaluate any differences in survival. Variables with \( P < 0.1 \) in the univariate analysis were incorporated into the proportional hazard model of Cox for multivariable analysis. Differences were deemed statistically significant at \( P < 0.05 \).

**Results**

**Expression profile of FGL1 on GEPIA 2 and its relation with HCC prognosis**

The expression profile of FGL1 in multiple malignant tumors was bioinformatically determined using the GEPIA
2 webserver. Expectedly, the expression of FGL1 in the liver hepatocellular carcinoma (LIHC) was higher than in any other malignant tumor tissues, and lower than in normal liver tissues (Fig. 1A). There was a significant difference in the expression of FGL1 between normal liver tissues and LIHC (Fig. 1B, $P<0.05$) (matched TCGA normal and GTEx data). Further, a search of existing OMICS data using the UAL-CAN website suggested that FGL1 expression was significantly related to individual cancer stages (Fig. 1C, $P<0.05$).

Based on the above results, it was speculated that FGL1 could be correlated to the prognosis of HCC patients. To further explore this correlation, the OncoLnc database was used to conduct a survival analysis based on the expression status of FGL1. The FGL1 expression level was found to be associated with the prognosis of HCC patients, with low FGL1 expression indicating poor overall survival (OS) (Fig. 1D, $P=0.023$).

### Evaluation of FGL1 expression in human HCC cell lines and HCC tissues

To further explore the positive results of bioinformatics analysis, FGL1 expression was tested in human HCC cell lines and HCC tissues. The expression profile of FGL1 in human HCC cell lines was determined by western blotting. A quantitative comparison, performed using the gray analysis of the western blot, revealed a lower FGL1 expression in the HCC-LM3, SK-Hep1, SMMC-7721, C3A, HepaG2, and non-tumorous liver tissues. C FGL1 expression in LIHC based on individual pathological stages by UALCAN online website. D Kaplan–Meier survival curves of LIHC patients with low and high FGL1 expression based on the OncoLnc Database. “*” signifies $P$ value $<0.05$.

---

**Fig. 1** FGL1 expression of HCC tissues was downregulated compared with paired normal tissues, and the downregulation of FGL1 was correlated with poor HCC prognosis. **A** FGL1 expression profile across all cancer samples and paired normal tissues on the basis of GEPIA. **B** The differential expression level of FGL1 in tumor and non-tumorous liver tissues. **C** FGL1 expression in LIHC based on individual pathological stages by UALCAN online website. **D** Kaplan–Meier survival curves of LIHC patients with low and high FGL1 expression based on the OncoLnc Database. “*” signifies $P$ value $<0.05$.
Huh7, and Hep3B cells, compared to the normal liver cell line (LO2) (Fig. 2A). Further, the FGL1 expression profile for 11 pairs of fresh tissues collected from HCC patients revealed that the expression was the lowest in HCC tissues, compared to normal and peri-tumor tissues (Fig. 2B). Similarly, as expected, FGL1 expression was lower in HCC tissues than in normal liver tissues (Fig. 2C). Notably, the IHC staining of TMAs also indicated that FGL1 expression was lower in HCC tissues compared to adjacent normal liver tissues (Fig. 2D). Overall, the above results confirmed that FGL1 expression in HCC tissues is lower than normal tissues, which also corroborates with the trend observed in the bioinformatics analysis.

Correlation analysis between FGL1 expression and the clinicopathological parameters of HCC

Based on the four grades of FGL1 expression, all patients were divided into high and low expression groups to probe the correlation between FGL1 expression levels and the clinicopathological parameters of HCC. FGL1 expression levels in HCC were found to be correlated with Edmondson grade and metastasis (Table 1, P < 0.05). However, no significant correlation of FGL1 expression was found with other clinical parameters (age, gender, tumor size, tumor number, microvascular invasion, HBsAg, cirrhosis, and AFP) (Table 1, P > 0.05).

Prognostic significance of FGL1 expression level for HCC

The statistical significance of various prospective HCC prognostic factors was determined using the Cox regression analysis. Based on a univariate Cox regression analysis, tumor number, Edmondson grade, metastasis, HBsAg and FGL1 expression level could all be prognostic factors for HCC (Table 2, P < 0.1). A multivariate Cox regression analysis was performed to further ensure that Edmondson grade, metastasis and FGL1 expression level were independent prognostic factors for HCC (Table 2, P < 0.05). Consistently, it was found that FGL1 expression significantly correlated with OS in HCC patients on the Kaplan–Meier survival curve, with low FGL1 expression being linked to a shorter OS (Fig. 3, P < 0.0001).

Discussion

While the diagnosis and treatment of HCC have improved in recent years, the prognosis of HCC patients is still poor. Various prognostic markers, such as AFP and AFU, have been employed extensively, but the specificity and sensitivity of these biomarkers are not sufficient [19]. The occurrence of false positives makes it challenging to differentiate early-stage HCC from other liver disorders such as acute hepatitis and cirrhosis [20]. Therefore, it is important to search for more convenient and more reliable markers that can facilitate early diagnosis and indicate the prognosis of HCC.

FGL1 is both a hepatic protectant and a hepatocyte mitogen involved in mitogenic and metabolic activity [21]. In the case of liver injury or acute inflammation, FGL1 expression levels increase [10, 15, 22], promoting the proliferation of normal hepatocytes in vivo. Similarly, FGL1 can also affect the proliferation of HCC cells. Downregulation of FGL1 in HCC cells may contribute to their growth and proliferation [23]. Further, FGL1 promotes hepatic cell proliferation by an autocrine mechanism, while inhibiting HCC cell proliferation via an intracrine pathway [24]. However, the exact role of FGL1 in HCC remains controversial. The present study was conducted to elucidate this role.

Previous studies have reported the downregulation of FGL1 in HCC, and a strong correlation between FGL1 expression and the differentiation status of malignant tumors [25]. The present study confirmed, using GEPIA 2, that FGL1 expression in HCC tissues is lower compared to normal liver tissues. Western blot analysis also confirmed that FGL1 expression is lower in most HCC cell lines (HCC-LM3, SK-Hep1, SMMC-7721, C3A, HepaG2, Huh7, and Hep3B cells) than normal liver cells (LO2). Furthermore, FGL1 expression in primary HCC tissues was also found to be lower than normal tissues and peri-tumor tissues. Moreover, FGL1 expression was significantly related to individual cancer stages, as determined through the UALCAN website. TMA results further demonstrated that FGL1 expression levels in HCC are correlated with the HCC’s Edmondson grade and metastasis. The significance of FGL1 as a prognostic marker for HCC was further confirmed using a survival analysis, which showed that FGL1 expression level is significantly correlated with OS in HCC patients (P < 0.05). Particularly, downregulation of FGL1 hints at poor OS. Multivariate Cox regression analysis confirmed that FGL1 expression level could be considered as a prognostic factor for HCC patients. Based on these data, it can be speculated that the FGL1 is linked to the progression and prognosis of HCC by functioning as a tumor suppressor.

Recent studies have increasingly focused on FGL1 for its possible role in the prognosis and treatment of various malignant tumors. In LKB1 mutant lung adenocarcinoma, loss of FGL1 was found to promote angiogenesis and epithelial-mesenchymal transition, leading to poor prognosis [26]. However, Yang et al. [16] reported that FGL1 upregulation is linked to poor prognosis of gastric cancer, contrary to the results of the present study in the context of HCC. The studies discussed above prove that FGL1 is associated with the prognosis of malignant tumors, and that it also plays a significant role in their treatment. A previous study has shown...
Fig. 2  FGL1 expression showed obvious downregulation in several human HCC cell lines and HCC tissues. A Determination of FGL1 expression in several human HCC cell lines and the normal liver cell line via western blot analysis. B Determination of FGL1 expression with 3 pairs of HCC tissues and peri-tumor tissues and paired normal liver tissues via western blot analysis. C Determination of FGL1 expression with 8 pairs of HCC tissues and paired normal liver tissues via western blot analysis. D IHC staining for tumor tissues and adjacent normal liver tissues from HCC patients in the TMA. N normal liver tissue, P peri-tumor tissue, C cancer tissue; the numbers before N, P and C represent the group number.
that the suppression of FGL1 inhibits the expression of caspase 3 and PARP1, thereby enhancing the inhibitory and apoptosis-inducing activities of gefitinib in the non-small cell lung cancer (NSCLC) cell line PC9/GR [27]. Similarly, Son et al. [28] reported that sorafenib-induced anti-tumor effects were enhanced by knocking down FGL1. Interestingly, high expression levels of FGL1 are related to high densities of LAG-3+ cells, confirming that FGL1 is a high-affinity ligand for LAG-3 [29]. It is also known that blocking the FGL1-LAG-3 pathway can enhance the activation of T cells and promote anti-tumor immunity [18]. Hence, targeting the FGL1-LAG-3 pathway, in addition to anti-PD1 therapy, could significantly improve the treatment of HCC patients for whom anti-PD1 therapy alone is not effective [30]. Notably, it has been found that the drug oxysophocarpine decreases FGL1 expression by downregulating IL-6-mediated JAK2/STAT3 signaling, ultimately enhancing the immunotherapeutic effect of CD8+ T cells against HCC in vivo and in vitro [31]. In the future, the treatment and prognosis of various malignant tumors could be improved by adjusting the expression of FGL1 through such drugs.

The present study is reinforced with clinical data, providing strong evidence for the prognostic significance of FGL1 for HCC. Nevertheless, the underlying mechanisms of the signaling pathways in HCC remain unclear. Future studies would continue to explore the detailed mechanisms that can explain the correlation between FGL1 and HCC.

Conclusions

The present study found that FGL1 expression is correlated with the progression and prognosis of HCC, suggesting that FGL1 could be a potential prognostic biomarker for HCC. Importantly, this study also provides a basis for further investigations of FGL1 in the context of HCC.

| Table 1 Expression of FGL1 in hepatocellular carcinoma tissues |
|-------------------------------- |---------------- |---------------- |---------------- |---------------- |
| Clinical parameters | Number | FGL1 expression | χ² | P value |
| | | Low | High |
| Age (years) | | | | |
| < 55 | 90 | 13 | 77 | |
| ≥ 55 | 147 | 22 | 125 | |
| Gender | | | | |
| Male | 190 | 26 | 164 | |
| Female | 47 | 9 | 38 | |
| Tumor size | | | | |
| ≤ 50 mm | 138 | 18 | 120 | |
| > 50 mm | 95 | 16 | 79 | |
| Tumor number | | | | |
| Single | 194 | 28 | 166 | |
| Multiple | 43 | 7 | 36 | |
| Edmondson grade | | | | |
| I + II | 146 | 17 | 129 | |
| III | 78 | 17 | 61 | |
| Metastasis | | | | |
| M0 | 210 | 26 | 184 | |
| M1 | 19 | 7 | 12 | |
| Microvascular invasion | | | | |
| Absence | 87 | 11 | 76 | |
| Presence | 88 | 15 | 73 | |
| HBs antigen | | | | |
| Negative | 46 | 7 | 39 | |
| Positive | 186 | 27 | 159 | |
| Cirrhosis | | | | |
| Negative | 78 | 16 | 62 | |
| Positive | 159 | 19 | 140 | |
| AFP(µg/L) | | | | |
| < 50 | 104 | 14 | 90 | |
| ≥ 50 | 86 | 14 | 72 | |

*Signifies P value < 0.05

Total number was less than 237 due to incomplete pathological data
Acknowledgements  
Not applicable.

Author contributions  
NH, HD and GR collected and analyzed the data, performed the experiments, drew figures and tables, and contributed in writing the manuscript. SW, XH and NH performed the experiments and statistical analysis; XT procured the funding for this study. XT, FZ, CY, SW participated in the design of the study, gave administrative or logistical support for this study, and reviewed drafts of the paper. All the authors agreed with the conclusions of this review and approved the final manuscript.

Funding  
This article was supported by the Zhejiang Provincial Medical Technology Plan Project (No. 2020KY052, 2017ZA007), the Zhejiang Provincial Natural Science Foundation of China (No. LY19H160037, LY17H160062), and the Zhejiang Provincial Science and Technology Project (No. 2018C37078).

Table 2  
Univariate and Multivariate Cox regression of the clinicopathological parameters in HCC patients

| Parameters                  | Univariate analysis | Multivariate analysis |
|-----------------------------|---------------------|-----------------------|
|                             | Coefficient | HR  | 95.0% CI For HR | P     | Coefficient | HR  | 95.0% CI For HR | P     |
| Age (<55 years/≥55 years)   | -0.295       | 0.744 | 0.370–1.498 | 0.408 |                |     |                |       |
| Gender (Male/Female)        | -0.199       | 0.819 | 0.370–1.814 | 0.623 |                |     |                |       |
| Tumor size (≤50 mm/>50 mm)  | 0.376        | 1.457 | 0.659–3.218 | 0.352 |                |     |                |       |
| Tumor number (Single/multiple) | 1.321     | 3.748 | 1.634–8.600 | 0.002* | 0.519       | 1.680 | 0.941–2.998 | 0.079 |
| Edmondson grade (I + II/III)| 1.276        | 3.582 | 1.650–7.779 | 0.001* | 1.076       | 2.932 | 1.751–4.909 | 0.000* |
| Metastasis (M0/M1)          | 0.842        | 2.320 | 0.894–6.023 | 0.084 | 1.402       | 4.062 | 2.139–7.712 | 0.000* |
| Microvascular invasion (−/+)| 0.062        | 1.064 | 0.494–2.292 | 0.874 |                |     |                |       |
| HBs antigen (−/+            | -1.025       | 0.359 | 0.127–1.014 | 0.053 | -0.033       | 0.968 | 0.532–1.760 | 0.915 |
| Cirrhosis (−/+               | 0.599        | 1.820 | 0.823–4.021 | 0.139 |                |     |                |       |
|AFP (<50 µg/L/≥50 µg/L)      | 0.251        | 1.285 | 0.598–2.762 | 0.520 |                |     |                |       |
| FGL1 (−/+                    | -0.924       | 0.397 | 0.171–0.922 | 0.032* | -0.861       | 0.423 | 0.247–0.725 | 0.002* |

*Signifies P value < 0.05

Fig. 3  
Kaplan–Meier survival analysis of HCC patients with different expression levels of FGL1 in TMA

Data availability  
The datasets supporting the conclusions of this article are included within the article.

Declarations

Conflict of interest  
The authors declare that they have no competing interests.

Ethical approval  
This study was authorized by the Ethics Committee of the Zhejiang Provincial People’s Hospital (2021QT150).

Consent to participate  
Informed consent was obtained from all individual participants included in the study.

Consent to publish  
Not applicable.

Open Access  
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics, 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

2. Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3

3. Zhang G, Ha SA, Kim HK et al (2012) Combined analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3

4. De Stefano F, Chacon E, Turcios L et al (2018) Novel biomarkers of fibrinogen-like protein 1 as a useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis Markers 32(4):265–271. https://doi.org/10.3233/DMA-2011-0878

5. Demchev V, Malana G, Vangala D et al (2013) Targeted deletion of fibrinogen-like protein 1 reveals a novel role in energy substrate utilization. PlaS ONE 8(3):e58084. https://doi.org/10.1371/journal.pone.0058084

6. Yu J, Li J, Shen J et al (2021) The role of fibrinogen-like proteins in cancer. Int J Biol Sci 17(4):1079–1087. https://doi.org/10.7150/ijbs.56748

7. Yamamoto T, Gotoh M, Sasaki H et al (1993) Molecular cloning and initial characterization of a novel fibrinogen-related gene, HFREP-1. Biochem Biophys Res Commun 193(2):681–687. https://doi.org/10.1016/0006-291X(93)90727-4

8. Rijken DC, Dirkx SPG, Luider TM et al (2006) Hepatocyte-derived fibrinogen-related protein-1 is associated with the fibrin matrix of a plasma clot. Biochem Biophys Res Commun 350(1):191–194. https://doi.org/10.1016/j.bbrc.2006.09.018

9. Wu HT, Chen SC, Ou H-Y et al (2013) Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity. FASEB J 34(2):2958–2967. https://doi.org/10.1096/fj.201301925R

10. Liu Z, Ukomadu C (2008) Fibrinogen-like protein 1, a hepatocyte derived protein is an acute phase reactant. Biochem Biophys Res Commun 365(4):729–734. https://doi.org/10.1016/j.bbrc.2007.11.069

11. Gao M, Zhan Y-Q, Yu M et al (2014) Hepassocin activates the EGFR/ERK cascades and induces proliferation of L02 cells through the Src-dependent pathway. Cell Signal 26(10):2161–2166. https://doi.org/10.1016/j.cellsig.2014.04.013

12. Wu H-T, Lu F-H, Ou H-Y et al (2013) The role of hepassocin in the development of non-alcoholic fatty liver disease. J Hepatol 59(5):1065–1072. https://doi.org/10.1016/j.jhep.2013.06.004

13. Haru H, Yoshimura H, Uchiha S et al (2001) Molecular cloning and functional expression analysis of a cDNA for human hepassocin, a liver-specific protein with hepatocyte mitogenic activity. Biochem Biophys Acta 1520(1):45–53. https://doi.org/10.1016/s0167-4781(01)00249-4

14. Han NK, Jung MG, Jeong YJ et al (2019) Plasma fibrinogen-like 1 as a potential biomarker for radiation-induced liver injury. Cells. https://doi.org/10.3390/cells8091042

15. Han H, Uchiha S, Yoshimura H et al (2000) Isolation and characterization of a novel liver-specific gene, hepassocin, upregulated during liver regeneration. Biochem Biophys Acta 1492(1):31–44. https://doi.org/10.1016/s0167-4781(00)00056-7

16. Zhang Y, Qiao HX, Zhou YT et al (2018) Fibrinogen-like-protein 1 promotes the invasion and metastasis of gastric cancer and is associated with poor prognosis. Mol Med Rep 18(2):1465–1472. https://doi.org/10.3892/mmr.2018.9097

17. Nayeb-Hashemi H, Desai A, Demchev V et al (2015) Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development. Biochem Biophys Res Commun 465(2):167–173. https://doi.org/10.1016/j.bbrc.2015.07.078

18. Wang J, Sannamed MF, Datar I et al (2019) Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176:334–347.e12. https://doi.org/10.1016/j.cell.2018.11.010

19. Luo P, Wu S, Yu Y et al (2020) Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res 26(2):599–603. https://doi.org/10.1007/s12253-019-00585-5

20. Tsuchiya N, Sawada Y, Endo I et al (2015) Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 21(37):10573–10583. https://doi.org/10.3748/wjg.v21.i37.10573

21. Li CY, Cao CZ, Xu WX et al (2010) Recombinant human hepassocin stimulates proliferation of hepatocytes in vivo and improves survival in rats with fulminant hepatic failure. Gut 59(6):817–826. https://doi.org/10.1136/gut.2008.171124

22. Yan J, Ying H, Gu F et al (2002) Cloning and characterization of a mouse liver-specific gene mHfrep-1, up-regulated in liver regeneration. Cell Res 12:353–361. https://doi.org/10.1038/sj.cr.7290317

23. Yang J, Yu Y, Wang N et al (2004) LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma. Oncogene 23(10):1939–1949. https://doi.org/10.1038/sj.onc.1207306

24. Cao MM, Xu WX, Li CY et al (2011) Hepassocin regulates cell proliferation of the human hepatic cells L02 and hepatocarcinoma cells through different mechanisms. J Cell Biochem 112(10):2882–2890. https://doi.org/10.1002/jcb.23202

25. Yu HT, Yu M, Li CY et al (2009) Specific expression and regulation of hepassocin in the liver and down-regulation of the correlation of HNF1alpha with decreased levels of hepassocin in human hepatocellular carcinoma. J Biol Chem 284(20):13335–13347. https://doi.org/10.1074/jbc.M806393200

26. Bie F, Wang G, Qu X et al (2019) Loss of FGL1 induces epithelial-mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma. Int J Onco 55(3):697–707. https://doi.org/10.38292/ijo.2019.4838

27. Sun C, Gao W, Liu J et al (2020) FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res 21(1):210. https://doi.org/10.1186/s12931-020-01477-y

28. Son Y, Shin NR, Kim SH et al (2021) Fibrinogen-like protein 1 modulates sorafenib resistance in human hepatocellular carcinoma cells. Int J Mol Sci. https://doi.org/10.3390/ijms22105330

29. Guo M, Yuan F, Qi F et al (2020) Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med 18(1):306. https://doi.org/10.1186/s12967-020-02469-8

30. Zhang WT, Liu TT, Wu M et al (2021) Development of a body-based immunoassay for the sensitive detection of fibrinogen-like protein 1. Acta Pharmacol Sin 42(11):1921–1929. https://doi.org/10.1038/s41401-021-00574-4

31. Wang J, Wei W, Tang Q et al (2020) Oxytetracycline suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-Lag-3 via reducing FGL1 expression. Cancer Med 9(19):7125–7136. https://doi.org/10.1002/cam4.3151

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.